MedTrace Logo

Utility of the Pharmacogenetic Information Provided by NEUROPHARMAGEN in the Treatment of Bipolar Depressionwith Bipolar Depression

NCT04923204 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2021-06-11

No results posted yet for this study

Summary

Evaluation of the impact of the genetic variation of individual genes on the therapeutic response and side effects profile in a cohort of well-characterized patients with bipolar depression, using NEUROPHARMAGEN.

Conditions

Interventions

DIAGNOSTIC_TEST

Pharmacogenomic-testing with NEUROPHARMAGEN

This observational retrospective study aims at evaluating the impact of the genetic variation in individual genes on the therapeutic response and side effects profile in a bipolar disorder cohort, using NEUROPHARMAGEN. NEUROPHARMAGEN is a pharmacogenomic-based decision support tool that helps clinicians in the selection and dosing of psychoactive drugs based on the integration of pharmacogenetic information.

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    collaborator OTHER

  • AB Biotics, SA

    lead INDUSTRY

Principal Investigators

  • Eduard Vieta, MD, PhD · Hospital Clinic of Barcelona

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-01
Primary Completion
2016-03-31
Completion
2019-12-05

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04923204 on ClinicalTrials.gov